Comment to: Intensive support recommendations for critically-ill patients with suspected or confirmed COVID-19 infection
Authors:
- Thiago Domingos CorrêaTCThiago Domingos Corrêa
- Gustavo Faissol Janot de MatosGMGustavo Faissol Janot de Matos
- Bruno de Arruda BravimBBBruno de Arruda Bravim
- Ricardo Luiz CordioliRCRicardo Luiz Cordioli
- Alejandra del Pilar Gallardo GarridoAGAlejandra del Pilar Gallardo Garrido
- Murillo Santucci Cesar de AssuncaoMAMurillo Santucci Cesar de Assuncao
- Carmen Silvia Valente BarbasCBCarmen Silvia Valente Barbas
- Karina Tavares TimenetskyKTKarina Tavares Timenetsky
- Roseny dos Reis RodriguesRRRoseny dos Reis Rodrigues
- Hélio Penna GuimarãesHGHélio Penna Guimarães
- Roberto RabelloRRRoberto Rabello
- Frederico Polito LomarFLFrederico Polito Lomar
Open Access
- 31 July 2020
- journal article
- letter
- Published by Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein in Einstein (São Paulo)
- Vol. 18, 1-2
Abstract
Dear Editor, In this issue of einstein journal (São Paulo), Corrêa et al., reported intensive support recommendations for critically-ill patients with suspected or confirmed infection by the new coronavirus (COVID-19).() Based on preliminary demonstration of efficacy of chloroquine, the authors suggested the use of hydroxychloroquine in monotherapy or combined with a macrolide (azithromycin or clarithromycin), to treat severe patients with COVID-19, admitted to the intensive care unit (ICU), to inhibit in vitro replication of severe acute respiratory syndrome coronavirus 2 [...] Dear Editor, In this issue of einstein journal (São Paulo), Corrêa et al., reported intensive support recommendations for critically-ill patients with suspected or confirmed infection by the new coronavirus (COVID-19).() Based on preliminary demonstration of efficacy of chloroquine, the authors suggested the use of hydroxychloroquine in monotherapy or combined with a macrolide (azithromycin or clarithromycin), to treat severe patients with COVID-19, admitted to the intensive care unit (ICU), to inhibit in vitro replication of severe acute respiratory syndrome coronavirus 2Keywords
This publication has 4 references indexed in Scilit:
- Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York StateJAMA, 2020
- Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19New England Journal of Medicine, 2020
- Intensive support recommendations for critically-ill patients with suspected or confirmed COVID-19 infectionEinstein (São Paulo), 2020
- Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitroCell Discovery, 2020